Literature DB >> 24038696

Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates.

Lucie Amoureux1, Julien Bador, Sakina Fardeheb, Cédric Mabille, Charlyne Couchot, Clémence Massip, Anne-Lise Salignon, Guillaume Berlie, Véronique Varin, Catherine Neuwirth.   

Abstract

Achromobacter xylosoxidans is an aerobic nonfermentative Gram-negative rod considered an important emerging pathogen among cystic fibrosis (CF) patients worldwide and among immunocompromised patients. This increased prevalence remains unexplained, and to date no environmental reservoir has been identified. The aim of this study was to identify potential reservoirs of A. xylosoxidans in hospital, domestic, and outdoor environments and to compare the isolates with clinical ones. From 2011 to 2012, 339 samples were collected in Dijon's university hospital, in healthy volunteers' homes in the Dijon area, and in the outdoor environment in Burgundy (soil, water, mud, and plants). We designed a protocol to detect A. xylosoxidans in environmental samples based on a selective medium: MCXVAA (MacConkey agar supplemented with xylose, vancomycin, aztreonam, and amphotericin B). Susceptibility testing, genotypic analysis by pulsed-field gel electrophoresis, and blaOXA-114 sequencing were performed on the isolates. A total of 50 strains of A. xylosoxidans were detected in hospital (33 isolates), domestic (9 isolates), and outdoor (8 isolates) samples, mainly in hand washing sinks, showers, and water. Most of them were resistant to ciprofloxacin (49 strains). Genotypic analysis and blaOXA-114 sequencing revealed a wide diversity among the isolates, with 35 pulsotypes and 18 variants of oxacillinases. Interestingly, 10 isolates from hospital environment were clonally related to clinical isolates previously recovered from hospitalized patients, and one domestic isolate was identical to one recovered from a CF patient. These results indicate that A. xylosoxidans is commonly distributed in various environments and therefore that CF patients or immunocompromised patients are surrounded by these reservoirs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24038696      PMCID: PMC3837737          DOI: 10.1128/AEM.02293-13

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  44 in total

1.  Strains of Achromobacter xylosoxidans from clinical material.

Authors:  B Holmes; J J Snell; S P Lapage
Journal:  J Clin Pathol       Date:  1977-07       Impact factor: 3.411

2.  Colonization by Alcaligenes xylosoxidans in children with cystic fibrosis: a retrospective clinical study conducted by means of molecular epidemiological investigation.

Authors:  D Moissenet; A Baculard; M Valcin; V Marchand; G Tournier; A Garbarg-Chenon; H Vu-Thien
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

3.  Prevalence of Pseudomonas aeruginosa in households of patients with cystic fibrosis.

Authors:  Thomas Regnath; Marion Kreutzberger; Stephan Illing; Rainer Oehme; Oliver Liesenfeld
Journal:  Int J Hyg Environ Health       Date:  2004-12       Impact factor: 5.840

4.  Chryseobacterium (Flavobacterium) meningosepticum outbreak associated with colonization of water taps in a neonatal intensive care unit.

Authors:  S N Hoque; J Graham; M E Kaufmann; S Tabaqchali
Journal:  J Hosp Infect       Date:  2001-03       Impact factor: 3.926

Review 5.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

6.  Investigation of hospital-acquired infections due to Alcaligenes denitrificans subsp. xylosoxydans by DNA restriction fragment length polymorphism.

Authors:  M Cheron; E Abachin; E Guerot; M el-Bez; M Simonet
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

7.  Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989-2003).

Authors:  Gabriel Aisenberg; Kenneth V Rolston; Amar Safdar
Journal:  Cancer       Date:  2004-11-01       Impact factor: 6.860

8.  Nosocomial colonization and infection by Achromobacter xylosoxidans.

Authors:  M E Reverdy; J Freney; J Fleurette; M Coulet; M Surgot; D Marmet; C Ploton
Journal:  J Clin Microbiol       Date:  1984-02       Impact factor: 5.948

Review 9.  Achromobacter xylosoxidans (Alcaligenes xylosoxidans subsp. xylosoxidans) bacteremia associated with a well-water source: case report and review of the literature.

Authors:  J B Spear; J Fuhrer; B D Kirby
Journal:  J Clin Microbiol       Date:  1988-03       Impact factor: 5.948

10.  Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data.

Authors:  Lucie Amoureux; Julien Bador; Eliane Siebor; Nathalie Taillefumier; Annlyse Fanton; Catherine Neuwirth
Journal:  J Cyst Fibros       Date:  2012-09-01       Impact factor: 5.482

View more
  27 in total

1.  Chronic Airway Colonization by Achromobacter xylosoxidans in Cystic Fibrosis Patients Is Not Sustained by Their Domestic Environment.

Authors:  Chloé Dupont; Estelle Jumas-Bilak; Clara Doisy; Fabien Aujoulat; Raphaël Chiron; Hélène Marchandin
Journal:  Appl Environ Microbiol       Date:  2018-11-15       Impact factor: 4.792

2.  Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study.

Authors:  B D Edwards; J Greysson-Wong; R Somayaji; B Waddell; F J Whelan; D G Storey; H R Rabin; M G Surette; M D Parkins
Journal:  J Clin Microbiol       Date:  2017-04-26       Impact factor: 5.948

3.  Environmental Distribution and Drug Susceptibility of Achromobacter Xylosoxidans Isolated from Outdoor and Indoor Environments.

Authors:  Sachiko Nakamoto; Misaki Sakamoto; Kana Sugimura; Yuki Honmura; Yuki Yamamoto; Natsumi Goda; Hiroo Tamaki; Naoto Burioka
Journal:  Yonago Acta Med       Date:  2017-03-09       Impact factor: 1.641

4.  Enrichment of Hydrogen Oxidizing Bacteria from High Temperature and Salinity Environments.

Authors:  Raquel G Barbosa; H Pieter J van Veelen; Vanessa Pinheiro; Tom Sleutels; Willy Verstraete; Nico Boon
Journal:  Appl Environ Microbiol       Date:  2020-11-30       Impact factor: 4.792

5.  Diverse Protein Architectures and α-N-Methylation Patterns Define Split Borosin RiPP Biosynthetic Gene Clusters.

Authors:  Aman S Imani; Aileen R Lee; Nisha Vishwanathan; Floris de Waal; Michael F Freeman
Journal:  ACS Chem Biol       Date:  2022-03-17       Impact factor: 4.634

Review 6.  Anatomical localization of commensal bacteria in immune cell homeostasis and disease.

Authors:  Thomas C Fung; David Artis; Gregory F Sonnenberg
Journal:  Immunol Rev       Date:  2014-07       Impact factor: 12.988

Review 7.  Achromobacter Infections and Treatment Options.

Authors:  Burcu Isler; Timothy J Kidd; Adam G Stewart; Patrick Harris; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

8.  Achromobacter xylosoxidans is the predominant Achromobacter species isolated from diverse non-respiratory samples.

Authors:  L Amoureux; J Bador; T Verrier; H Mjahed; C DE Curraize; C Neuwirth
Journal:  Epidemiol Infect       Date:  2016-08-18       Impact factor: 4.434

9.  Isolation of multiple drug-resistant enteric bacteria from feces of wild Western Lowland Gorilla (Gorilla gorilla gorilla) in Gabon.

Authors:  Pierre Philippe Mbehang Nguema; Torahiko Okubo; Sayaka Tsuchida; Shiho Fujita; Juichi Yamagiwa; Yutaka Tamura; Kazunari Ushida
Journal:  J Vet Med Sci       Date:  2015-01-30       Impact factor: 1.267

10.  Comparative genomics of non-pseudomonal bacterial species colonising paediatric cystic fibrosis patients.

Authors:  Kate L Ormerod; Narelle M George; James A Fraser; Claire Wainwright; Philip Hugenholtz
Journal:  PeerJ       Date:  2015-09-15       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.